The history of cytotoxic drugs in the treatment of malignant tumors is only 60 years old. In the 1970s, cisplatin, carboplatin, adriamycin and other drugs (second generation drugs) entered the clinic, and only then the era of drug treatment for lung cancer was opened. After the 1990s, with the gradual release of paclitaxel, vincristine, gemcitabine and other (third-generation) drugs and related clinical trial studies, the combination of these drugs with platinum drugs has shown better and better efficacy and less toxic side effects than previous chemotherapy regimens for the treatment of lung cancer, thus improving the quality of life and prolonging the survival time of lung cancer patients. The combination of these drugs with platinum-based drugs has shown increasingly better efficacy and less toxic side effects than previous chemotherapy regimens, thereby improving the quality of life and prolonging the survival of lung cancer patients, thus establishing the indispensable role of chemotherapy in the treatment of lung cancer. The following are the chemotherapy regimens commonly used for advanced non-small cell lung cancer (NSCLC): 1. Vincristine + cisplatin (NC) regimen: It is an early three-generation regimen. In a clinical phase III study by the Southwest Oncology Collaborative Group (SEOG), 206 patients with advanced non-small cell lung cancer were randomized to the vincristine + cisplatin group and the cisplatin monotherapy group. Study results: 26% overall effective rate, median survival of 8 months, and 1-year survival rate of 36%, significantly better than cisplatin alone. Another randomized controlled study conducted in Europe compared the NC, vincristine + cisplatin and vincristine monotherapy regimens with 612 patients enrolled and found that the NC regimen had a significantly higher overall efficiency and median survival than the latter two groups, respectively Results found that the NC regimen had a significantly higher overall efficiency and median survival than the latter two groups, respectively, 30% vsl 9% vsl 4% and 40 weeks vs 32 weeks vs 31 weeks. In contrast, in a randomized study of 121 patients by Depiere et al, the NC regimen had an effective rate of 43% and a median survival of 33 weeks. The NC regimen subsequently had better results in several phase III studies in postoperative adjuvant chemotherapy for NSCLC: improved survival time in stage IIIA patients, with a nearly 15% increase in 5-year survival. 2. Gemcitabine + cisplatin (GC) regimen: It is one of the commonly used regimens for NSLSC recently. In a phase III clinical study published in 1999, comparing the GC regimen with the 1st generation standard regimen EP (cisplatin + etoposide), the efficiency was 40,6% vs. 21,9% (P=O,02), the median time to disease progression was 6,9 months vs. 4,3 months (P=O,01), and the median survival time was 8.7 months vs. 7,2 months (P=O,40). Subgroup analysis of different histological types in the JMDB study (a clinical phase III randomized controlled study) showed that the GC regimen had a better efficacy of 36, 7% in squamous carcinoma. “The Gemcitabine Non-Small Cell Lung Cancer Meta-Analysis Group analyzed 13 clinical trials with 4,555 patients and found a weak survival advantage over other triple-generation agents plus platinum-based chemotherapy regimens, with a 3,9% increase in 1-year*** survival, suggesting a slight advantage of gemcitabine plus platinum-based regimens over triple-generation regimens. The advantage was slight. 3, paclitaxel ten cisplatin (PC) regimen: is one of the treatment options for NSCLC. A phase III clinical study in the United States compared paclitaxel + cisplatin (PC) regimen and cisplatin + etoposide (EP) regimen, and the results showed that the efficiency was 27,7% vs. 12,4%, median survival time was 9,9 months vs. 7,6 months, and 1-year survival rate was 38,9% vs. 31,8%, respectively. This PC regimen replaced the EP regimen as the standard first-line treatment regimen for advanced NSCLC. The PC regimen was used as a control group in clinical studies of chemotherapy regimens for many years to come. However, a retrospective analysis of chemotherapy regimens for advanced NSCLC in 2007 showed that the PC regimen was comparable to other three-generation platinum-containing regimens in terms of recent efficiency, but had a shorter disease-free time (PFS) and was not a superior first-line chemotherapy regimen for advanced NSCLC. 4. Doxorubicin + cisplatin (DC) regimen: It is one of the regimens for NSCLC. A large international multicenter phase III clinical study with 1200 patients from 28 countries, comparing DC regimen with NC regimen, the efficiency was 32%: 25% (P=0, 029), the median survival was 11, 3 months: 10, 1 month, and the 1-year survival rate was 46%: 41% (P=O. 044). In the study***, one triple-generation regimen was found to outperform another triple-generation regimen in terms of efficiency and survival. In the study of second-line treatment regimens for NSCLC in the JMEI trial comparing single-agent pemetrexed regimens with single-agent docetaxel regimens, there was no significant difference in overall efficacy and median survival, and stratified analysis found that the docetaxel group was superior to the pemetrexed group in the pathologically staged squamous cancer group, with median survival times of 7, 4 months: 6, 2 months, respectively (P=O, 018). 5. pemetrexed + cisplatin regimen: is a recently introduced regimen for the treatment of NSCLC. In a multicenter phase III clinical study with l725 patients comparing pemetrexed + cisplatin (CP) with gemcitabine + cisplatin (CG), the efficiency of the two groups was similar, 30, 6%: 28, 2%, respectively, and the median survival time was 10, 3 months in both groups. In the subgroup analysis by histological type, it was found that the CP regimen group had better efficiency and median survival time than the CG regimen group in non-squamous cancer patients, 32.0%: 25.2% and 12.6 months: 10.9 months, respectively, and the CG regimen group had better efficiency and median survival time than the CP regimen group in squamous cancer group, 36.7%: 26.9% and 10.8 months: 9.4 months, respectively. The CP regimen was significantly lower than the CG regimen in terms of toxic side effects of chemotherapy, especially in terms of severe hematologic toxicity. And in the subsequent S380 clinical trial, 260 patients with advanced NSCLC with non-squamous histological type were randomized to compare the pemetrexed + carboplatin (PC) regimen with the docetaxel + carboplatin (DC) regimen. The results: the PC group and the DC group had the same median disease progression-free time (PFS) and median survival time were essentially the same and did not show histological type re-advantage: the PC regimen was significantly better than the DC regimen in terms of toxic side effects of chemotherapy.